1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Capital Structure
3. Valuation
Discussion
Symbol
RGNT
Event Date
2025-12-04
Sector
Health Care
Subsector
Health Care Equipment & Supplies
Offer Range
$8.00
Shares Offered
1.25M
Shares Outstanding Pre-IPO
5.59M
5.59M
$39.4M
22.4%
Implied Upside vs Midpoint
Description
We are a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients. Our current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Our lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. GelrinC was approved as a device, with a Conformité Européene, or CE, mark in Europe, in 2017 (number 3900600CE02); we plan to identify strategic partners in Europe to bring our product to market. While we currently do not have any strategic partners in place in Europe, we plan to engage strategic partners in Europe in the future. With GelrinC, we aim to bring to market a product for the therapy of an unmet need for the large market of cartilage injuries in the knee. Because GelrinC serves as an impenetrable barrier that stops cells from migrating away from the wound’s edges, we believe our product is the only product that helps to regenerate cartilage inwards from the edges of the cell walls. Creating new contiguous tissue is not the natural, lowest energy, alternative for cartilage cells. If such cells were left alone, they would tend to migrate and either not create new cartilage tissue or create cartilage tissue that is fibrotic (containing an excessive deposition of extracellular matrix, leading gradually to the disturbance and finally to loss of the original tissue architecture and function). By GelrinC creating such impenetrable barrier and thereby preventing the migration of the cells, the cells are forced to take a different route of creating aggregate and contiguous tissue. Unlike GelrinC, cellular products used by competing companies require a plug of two layers of which the lower layer is a mineral scaffold, which is a foreign body material that has been engineered to be inserted into the bone tissue even though the bone is often healthy. Additionally, GelrinC does not have any biological activity. As a result, we believe our product offers a simple and economic procedure, which we believe will allow patients to recover quickly with potentially long-term outcomes. --- We are an Israeli corporation based in Israel and incorporated in 2004. Our address is 60 Medinat Hayehudim, Herzliya 4676652, Israel. Our telephone number is +972.9.960.1917. Our website address is www.regentis.co.il.
Post-IPO economic shares by class, valued at the offer midpoint.
| Class | Shares | % Economic | Est. value |
|---|---|---|---|
Ordinary Shares (listed) | 5.18M | 92.6% | $41.4M |
Warrants (outstanding) n/a · Generally exercisable into Ordinary Shares (warrants underlying 411,572 Ordinary Shares) | 411.57K | 7.4% | $3.3M |
| Total economic shares | 5.59M | 100% | $44.7M |
Regentis Biomaterials, Ltd. annual income statement and balance sheet, FY 2023 to FY 2025, as reported in SEC filings.
| Metric | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Operating income | ($1.9M) | $932K | ($7.0M) |
| Net income | ($4.1M) | $4.8M | ($13.6M) |
| Metric | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Total assets | — | $482K | $7.6M |
| Total liabilities | — | $6.5M | $2.9M |
| Total equity | ($45.9M) | ($41.1M) | $4.7M |
| Cash & equivalents | — | — | $7.4M |